infectious-diseases-2018-posters-abstracts

3 / 35

Infectious Diseases 2018 Journal of Prevention and Infection Control
ISSN: 2471-9668 Page 41
June 07-08, 2018
London, UK
8th Edition of International Conference on
Infectious Diseases
It would be informative for rational design of vaccines and
symptommanagement-therapies to do disease-progression from
infection stage gene expression profiling microarray studies for
parasitic infections. This would be the study of host cells infected
or other cells affected by the parasitic disease but not infected, at
different stages of the infection to see what is the progression of
parasite genes turned on/off up/down-regulated and the same for
the host genes. This would give valuable data from infection of cell
to cell death programme of say an HIV-infected T-cell. This could
also be done for non-virus parasites such as bacterial infections,
and nematode infections as well as say malaria. This could give
information about how to rationally design post-infection vaccines
if epitopes are created by the parasite due to particular gene
expression patterns at any stage from initial infection to later
stages. Later-stage vaccines could be designed to stimulate the
host immune system against later stages of parasitic epitopes
allowing later-stage vaccine intervention, where vaccination
has not been possible before infection and yet a strong vaccine-
stimulated immune response could cause later-stage elimination
of the parasitic infection or at least amelioration by bringing down
the levels of infectious agents. Vaccines can be rationally designed
also for immune system elimination of infectious agent to fend
off attempted infection. Thorough studies of gene expression
profiles of host and parasite at all stages of the infection process
and infection progression could allow rational design of drugs to
counter symptoms. Annotation of all the studies described with
gene/protein function data could allow valuable insights.
Recent Publications
1. Shi Z, Derow C K and Zhang B (2010) Co-expression
module analysis reveals biological processes, genomic
gain, and regulatory mechanisms associated with breast
cancer progression. BMC Systems Biology 4:74.
2. Aranda B, Achuthan P, Alam-Faruque Y, Armean I, Bridge
A, Derow C, Feuermann M, Ghanbarian A T, Kerrien S,
Khadake J, Kerssemakers J, Leroy C, Menden M, Michaut
M, Montecchi-Palazzi L, Neuhauser SN, Orchard S, Perreau
V, Roechert B, van Eijk K and Hermjakob H (2009) The
IntAct molecular interaction database in 2010. Nucleic
Acids Research 38(1):D525–D531
3. Chatr-aryamontri A, Kerrien S, Khadake J, Orchard S, Ceol
A, Licata L, Castagnoli L, Costa S, Derow C and Huntley
R (2008) MINT and IntAct contribute to the Second
BioCreative challenge: serving the text-mining community
with high quality molecular interaction data. Genome
Biology doi: 10.1186/gb-2008-9-s2-s5.
4. Kerrien S, Alam-Faruque Y, Aranda B, Bancarz I, Bridge
A, Derow C, Dimmer E, Feuermann M, Friedrichsen A,
Huntley R, Kohler C, Khadake J, Leroy C, Liban A, Lieftink C,
Montecchi-Palazzi L, Orchard S, Risse J, Robbe K, Roechert
B, Thorneycroft D, Zhang Y, Apweiler R and Hermjakob
H (2007) IntAct--open source resource for molecular
interaction data. Nucleic Acids Research 35:D561-5.
5. Chassagnole C, Jackson R C, Hussain N, Bashir L, Derow
C, Savin J and Fell D A (2006) Using a mammalian cell
cycle simulation to interpret differential kinase inhibition
in anti-tumour pharmaceutical development. Biosystems
83(2-3):91-7.
Biography
Catherine K Derow research is focused on applying Systems Biology to Ge-
nomics and Proteomics as a means of solving health problems and answering
important questions in the field of the Life Sciences. She currently works as an
Associate for Biopharma Vantage, a competitive intelligence provider for Life
Sciences companies. She has worked for Physiomics plc. on in silico anti-cancer
therapeutics development, as well as at the European Bioinformatics Institute
on the database IntAct, a molecular interactions resource, in the Proteomics
section. She has also served as an expert invited by the European Union to eval-
uate research proposals as part of a panel to aid in the selection of projects for
fellowship funding.
Host and parasite gene expression profiling through time from infection
to later stages of disease to allow rational design of traditional
vaccines, later-stage vaccines and therapies to treat symptoms
Catherine K Derow
Catherine Kari Derow Limited, UK
Catherine K Derow, J Prev Infect Cntrol 2018, Volume 4
DOI: 10.21767/2471-9668-C1-003